Displaying drugs 551 - 575 of 903 in total
Bismuth oxide
Experimental
Bismuth subcarbonate
Experimental
Vet approved
Resolvin E1
Resolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).
Investigational
Bisegliptin
Bisegliptin is a compound for the treatment of type 2 diabetes. It is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion and lowering blood glucose levels without hypoglycemic effects.
Investigational
Bisphosphocin Nu-3
Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).
Investigational
EMB-01
EMB-01 is under investigation in clinical trial NCT03797391 (A Dose Escalation Study of EMB-01 in Participants With Advanced/metastatic Solid Tumors).
Investigational
CTA018
CTA018 is a member of a new class of vitamin D analogues with a dual mechanism of action, called Vitamin D Signal Amplifiers. This proprietary new drug is both a potent inhibitor of CYP24 (the enzyme responsible for the breakdown of vitamin D) and a potent activator of vitamin D...
Investigational
Menadione bisulfite
Experimental
Bisoxatin acetate
Experimental
MM-111
MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.
Investigational
AMG-900
Investigational
Calcium
Calcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. The skeleton acts as a major mineral storage site for the element and releases Ca2+ ions into the bloodstream under controlled conditions. Circulating calcium is either in the...
Nutraceutical
beta-D-fructofuranose 1,6-bisphosphate
Experimental
Zinc glycinate
Glycoprotein marker of gastrointestinal cancer.
Experimental
Matched Iupac: … zinc(2+) bis(2-aminoacetate) …
ATG-101
ATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors, while delivering enhanced anti-tumor activity, with an improved safety profile.
Investigational
A-dmDT390-bisFv(UCHT1)
A-dmDT390-bisFv(UCHT1) is under investigation in clinical trial NCT02943642 (Safety and Effectiveness of A-dmdt390-bisfv(ucht1) Fusion Protein in Subjects With Mycosis Fungoides).
Investigational
Bisindolylmaleimide I
Experimental
Bisindolylmaleimide VIII
Experimental
Fosfructose
Experimental
Inositol 1,3-Bisphosphate
Experimental
Lomvastomig
Lomvastomig is under investigation in clinical trial NCT04785820 (A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus).
Investigational
Nezastomig
Nezastomig is under investigation in clinical trial NCT06085664 (A Pilot Presurgical Trial of REGN5678 (Anti-psma X CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy).
Investigational
Ubamatamab
Ubamatamab is under investigation in clinical trial NCT03564340 (Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers).
Investigational
Semapimod
Semapimod has been used in trials studying the treatment of Crohn Disease.
Investigational
Matched Iupac: … N,N'-bis({3,5-bis[(1E)-1-(carbamimidamidoimino)ethyl]phenyl})decanediamide …
Displaying drugs 551 - 575 of 903 in total